NDA 050750/S-050

SUPPLEMENT APPROVAL

Baxter Healthcare Corporation
Attention: Aiste Kirkute-Entremont
RA Principal Specialist
25212 W. Illinois Route 120
Round Lake, IL 60073

Dear Aiste Kirkute-Entremont:

Please refer to your supplemental New Drug Application (sNDA) dated and received December 15, 2023, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for ZOSYN® (piperacillin and tazobactam) injection.

We also refer to our approval letter dated April 11, 2024, which contained the following error: Residual solvent limits for (b) (4) needs to be corrected to Residual solvent limits for (b) (4) on Page 1.

This replacement approval letter incorporates the correction of the error. The effective approval date will remain April 11, 2024, the date of the original approval letter.

This Prior Approval supplemental new drug application provides for:

Addition of (b) (4) an alternate manufacturing site for the drug substance tazobactam, USP with reference to DMF (b) (4).

Addition of (b) (4) as drug substance testing (non-routine) site to test (b) (4) impurity (b) (4).

Addition of (b) (4) a drug substance testing site (b) (4) for Tazobactam.

Revisions to the drug substance specification specific to proposed drug substance manufacturing site (b) (4) as follows:

- Addition of new analytical methods for (b) (4) residual solvents for testing of the drug substance manufactured (b) (4) (b) (4).
- Widening of the limit (b) (4)
- Widening of the limit for total aerobic microbial count (b) (4) (b) (4)

- Addition of residual solvent limits (b) (4) (b) (4), widening of the limit (b) (4) and removal of residual solvent test (b) (4).
- Tightening of the limit for bacterial endotoxins (b) (4) (b) (4).
- Removal of (b) (4) from the drug substance specification.
- Removal of the test and its acceptance criteria for (b) (4) impurity.

Revisions to the drug product specification. as follows:

- Addition of a new analytical method (b) (4), (b) (4), piperacillin assay and tazobactam assay, used for testing of the drug product.
- Addition of a new analytical method for related compounds, used for testing of the drug product.
- Addition of a second test and acceptance criteria (b) (4) (b) (4) for piperacillin and tazobactam in accordance with ICH Q6A.
- Widening of Piperacillin and Tazobactam assay limits (b) (4) (b) (4) of Label Claim and concentration expression in g/100mL for each drug product presentation was added.
- Addition of a new test for (b) (4) impurities) with a limit (b) (4)
- Addition of test for "Largest Individual Unidentified Related Compound" in accordance with ICH Q3B with a limit (b) (4)
- Revision of the test name (b) (4) to "Largest Individual Identified Other Related Compound" to indicate that the specification is only for identified compounds.
- Revision of the test name from (b) (4) impurity to (b) (4) (b) (4) to reflect the USP naming.
- Change units of measurement (b) (4) to EU/ml and recalculate acceptance criteria for bacterial endotoxins.
- Addition of residual solvent and elemental impurities compliance statements as per USP<467> (Option I) and USP<232/233>, respectively.

APPROVAL

We have completed our review of this supplemental application, as amended. This supplement is approved.

We remind you that you must comply with reporting requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact Janell Artis, PharmD., Regulatory Business Process Manager at email: Janell.Artis@fda.hhs.gov, or (301) 796 – 6309.

Sincerely,

{See appended electronic signature page}

Gurpreet Gill-Sangha, Ph.D.
Supervisor
Division of Product Quality Assessment II
Office of Product Quality Assessment I
On behalf of:
David Lewis, Ph.D.
Division of Product Quality Assessment XI
Office of Product Quality Assessment II
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Gurpreet
Gill Sangha

Digitally signed by Gurpreet Gill Sangha
Date: 4/30/2024 10:27:19AM
GUID: 5135f2ad000117842392c50c36c7f28a